1.88

4.44% 0.08

After Hours: 1.88

Actinium Pharmaceuticals Inc (ATNM)

Overview News Price History Option Chain Discussions Forecast Stock Split

Actinium Pharmaceuticals Inc stock is traded at $1.88, with a volume of 164.07K. It is up +4.44% in the last 24 hours and down -5.53% over the past month. Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.

Previous Close:

$1.80

Open:

$1.8

24h Volume:

164.07K

Relative Volume:

0.21

Market Cap:

$57.95M

Revenue:

$1.05M

Net Income/Loss:

$-48.82M

P/E Ratio:

-1.033

EPS:

-1.82

Net Cash Flow:

$-47.49M

1W Performance:

+2.17%

1M Performance:

-5.53%

6M Performance:

-75.99%

1Y Performance:

-68.24%

1-Day Range:

$1.80

$1.895

1-Week Range:

$1.77

$1.93

52-Week Range:

$1.33

$10.24

Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile

Name

Actinium Pharmaceuticals Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

646-767-3870

Address

275 Madison Avenue, 7th Floor, New York, NY

Employee

Twitter

@actiniumpharma

Next Earnings Date

2024-08-12

Latest SEC Filings

ATNM's Discussions on Twitter

Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-21-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-08-22	Initiated	Cantor Fitzgerald	Overweight
Aug-25-22	Initiated	B. Riley Securities	Buy
Nov-05-20	Initiated	Alliance Global Partners	Buy
Dec-06-17	Initiated	B. Riley FBR, Inc.	Buy
Oct-23-17	Resumed	ROTH Capital	Buy
Sep-14-17	Initiated	Maxim Group	Buy
Aug-25-16	Initiated	ROTH Capital	Buy
Feb-29-16	Initiated	H.C. Wainwright	Buy
Oct-15-15	Initiated	FBR Capital	Outperform
Oct-01-14	Initiated	MLV & Co	Buy
Jul-22-14	Initiated	Canaccord Genuity	Buy

View All

Actinium Pharmaceuticals Inc Stock (ATNM) Latest News

12:49 PM

S&P 500 Down Over 100 Points; Actinium Pharmaceuticals Shares Plunge - MSN

12:49 PM

Sep 25, 2024

Comparing ARS Pharmaceuticals (NASDAQ:SPRY) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World

Sep 25, 2024

Actinium Pharmaceuticals (ATNM) vs. Its Rivals Head to Head Comparison - Defense World

Sep 25, 2024

Sep 24, 2024

Bank of New York Mellon Corp Increases Position in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World

Sep 24, 2024

Sep 23, 2024

Actinium Pharmaceuticals reports data from Phase III trial of AML treatment - Clinical Trials Arena

Sep 23, 2024

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Sep 23, 2024

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Average Rating of “Moderate Buy” by Brokerages - Defense World

Sep 23, 2024

Sep 22, 2024

Stocks of the Hour: Amplia Therapeutics, Wellard, Anax Metals - ShareCafe

Sep 22, 2024

Stocks of the Hour: Amplia Therapeutics, Wellard, Anax Metals - Finance News Network

Sep 22, 2024

Sep 21, 2024

Before Buying Anterix Inc (NASDAQ: ATEX) Stock, Read This First - Stocks Register

Sep 21, 2024

Sep 20, 2024

Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology - PR Newswire

Sep 20, 2024

Sep 19, 2024

Australia's Amplia Therapeutics rises as US FDA fast-tracks cancer drug - XM

Sep 19, 2024

Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha

Sep 19, 2024

Sep 18, 2024

Stock Analysts’ Downgrades for September 18th (ATNM, BHR, CALX, FITB, MEDP, MMSI, MOH, MTRX, NPK, PRMW) - Defense World

Sep 18, 2024

Sep 17, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc.ATNM - PR Newswire

Sep 17, 2024

Sep 09, 2024

Lutetium-177 Industry Research Report 2024: Carrier Added Lutetium-177, Non-Carrier-Added Lutetium-177 - GlobeNewswire Inc.

Sep 09, 2024

Sep 06, 2024

ATNM: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle

Sep 06, 2024